FDA Clears Path for Vanda Pharmaceuticals' Motion Sickness Drug Trial

The FDA has lifted the partial clinical hold on Vanda Pharmaceuticals' motion sickness drug tradipitant, allowing the company to extend clinical studies and eliminating the need for an additional six-month dog toxicity study. The FDA agreed with Vanda's position that motion sickness is an acute, self-limiting physiologic response rather than a chronic or chronic-intermittent condition. The ongoing review of tradipitant's new drug application for motion sickness prevention remains on track.